# Almonertinib Plus Metronomic Oral Vinorelbine

> **NCT05663177** · — · UNKNOWN · sponsor: **Fujian Cancer Hospital** · enrollment: 40 (estimated)

## Conditions studied

- EGFR
- NSCLC
- Third-generation TKI

## Interventions

- **DRUG:** Almonertinib and metronomic oral vinorelbine

## Key facts

- **NCT ID:** NCT05663177
- **Lead sponsor:** Fujian Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-12-20
- **Primary completion:** 2023-12-20
- **Final completion:** 2024-06-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2022-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05663177

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05663177, "Almonertinib Plus Metronomic Oral Vinorelbine". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05663177. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*